| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... N Engl J Med 2016 (375), 311-322, 2016 | 7829 | 2016 |
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetes care 35 (6), 1364-1379, 2012 | 5268* | 2012 |
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes DJ Drucker, MA Nauck The Lancet 368 (9548), 1696-1705, 2006 | 4842 | 2006 |
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetes care 38 (1), 140-149, 2015 | 3786 | 2015 |
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetologia 55, 1577-1596, 2012 | 3046* | 2012 |
| Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... DIABETOLOGIA 56 (3), 680-680, 2013 | 2186* | 2013 |
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus MA Nauck, MM Heimesaat, C Ørskov, JJ Holst, R Ebert, W Creutzfeldt J Clin Invest 91, 301-307, 1993 | 2038 | 1993 |
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. MA Nauck, MM Heimesaat, C Orskov, JJ Holst, R Ebert, W Creutzfeldt The Journal of clinical investigation 91 (1), 301-307, 1993 | 2022 | 1993 |
| Reduced incretin effect in type 2 (non-insulin-dependent) diabetes MA Nauck, F Stöckmann, R Ebert, W Creutzfeldt Diabetologia 29 (1), 46-52, 1986 | 1815 | 1986 |
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in … M Nauck, A Frid, K Hermansen, NS Shah, T Tankova, IH Mitha, ... Diabetes care 32 (1), 84-90, 2009 | 1550 | 2009 |
| Glucagon-like peptide 1 (GLP-1) TD Müller, B Finan, SR Bloom, D D'Alessio, DJ Drucker, PR Flatt, ... Molecular metabolism 30, 72-130, 2019 | 1457 | 2019 |
| Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients MA Nauck, N Kleine, C Ørskov, JJ Holst, B Willms, W Creutzfeldt Diabetologia 36, 741-744, 1993 | 1451 | 1993 |
| Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses MA NAUCK, E HOMBERGER, EG SIEGEL, RC ALLEN, RP EATON, ... The Journal of Clinical Endocrinology & Metabolism 63 (2), 492-498, 1986 | 1216 | 1986 |
| COVID-19 and diabetes mellitus: from pathophysiology to clinical management S Lim, JH Bae, HS Kwon, MA Nauck Nature Reviews Endocrinology 17 (1), 11-30, 2021 | 1211 | 2021 |
| Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects CF Deacon, MA Nauck, M Toft-Nielsen, L Pridal, B Willms, JJ Holst Diabetes 44 (9), 1126-1131, 1995 | 1182 | 1995 |
| Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans MA Nauck, U Niedereichholz, R Ettler, JJ Holst, C Ørskov, R Ritzel, ... American Journal of Physiology-Endocrinology And Metabolism 273 (5), E981-E988, 1997 | 1169 | 1997 |
| GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art MA Nauck, DR Quast, J Wefers, JJ Meier Molecular metabolism 46, 101102, 2021 | 1109 | 2021 |
| Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on … MA Nauck, G Meininger, D Sheng, L Terranella, PP Stein Diabetes, Obesity and Metabolism 9 (2), 194-205, 2007 | 975 | 2007 |
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European … SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ... Diabetologia 58, 429-442, 2015 | 934 | 2015 |
| Incretin hormones: Their role in health and disease MA Nauck, JJ Meier Diabetes, Obesity and Metabolism 20 (S1), 5-21, 2018 | 835 | 2018 |
Jens Juul HolstProfessor of Medical Physiology, University of CopenhagenVahvistettu sähköpostiosoite verkkotunnuksessa sund.ku.dk
